MyoKardia announces design of phase 3 EXPLORER-HCM study evaluating mavacamten in oHCM
MyoKardia announced the design of its pivotal Phase 3 EXPLORER-HCM clinical trial to evaluate use of mavacamten for potential treatment of patients with symptomatic oHCM. The company plans to conduct this study along with a long-term extension study to support registration. May 21, 2018